Predictor factor of survival in advanced hepatocellular carcinoma treated with sorafenib ∼a multicenter study∼

被引：0
|
作者：
Ogawa, Chikara [1 ,6 ]
Morita, Masahiro [1 ]
Omura, Akina [1 ]
Shibatoge, Mitsushige [1 ]
Tsutsui, Akemi [2 ]
Senoh, Tomonori [2 ]
Nagano, Takuya [2 ]
Takaguchi, Kouichi [2 ]
Tani, Joji [3 ]
Morishita, Asahiro [3 ]
Yoneyama, Hirohito [3 ]
Masaki, Tsutomu [3 ]
Moriya, Akio [4 ]
Ando, Masaharu [4 ]
Deguchi, Akihiro [5 ]
Kudo, Masatoshi [6 ]
机构：
[1] Takamatsu Red Cross Hosp, Dept Gastroenterol & Hepatol, Takamatsu, Kagawa, Japan
[2] Kagawa Prefectural Cent Hosp, Dept Hepatol, Takamatsu, Kagawa, Japan
[3] Kagawa Univ, Fac Med, Dept Gastroenterol & Neurol, Takamatsu, Kagawa, Japan
[4] Mitoyo Gen Hosp, Dept Gastroenterol, Kanonji, Japan
[5] Kagawa Rosai Hosp, Dept Gastroenterol, Marugame, Japan
[6] Kindai Univ, Fac Med, Dept Gastroenterol & Hepatol, Higashiosaka, Osaka, Japan
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O1-6-4
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Survival of Hepatocellular Carcinoma Patients Treated with Sorafenib beyond Progression
    Apostolidis, Leonidas
    Pfeiffenberger, Jan
    Gotthardt, Daniel
    Radeleff, Boris
    Mehrabi, Arianeb
    Schemmer, Peter
    Jaeger, Dirk
    Schirmacher, Peter
    Stremmel, Wolfgang
    Schulze-Bergkamen, Henning
    Springfeld, Christoph
    Weiss, Karl Heinz
    GASTROINTESTINAL TUMORS, 2018, 5 (1-2) : 38 - 46
  • [42] Doxorubicin and sorafenib improves survival in patients with advanced hepatocellular carcinoma
    Lisa Hutchinson
    Nature Reviews Clinical Oncology, 2011, 8 (2) : 61 - 61
  • [43] The impact of post-progression survival on overall survival of patients with advanced hepatocellular carcinoma treated by sorafenib therapy
    Terashima, Takeshi
    Yamashita, Tatsuya
    Takata, Noboru
    Nakagawa, Hidetoshi
    Arai, Kuniaki
    Kagaya, Takashi
    Mizukoshi, Eishiro
    Honda, Masao
    Kaneko, Shuichi
    HEPATOLOGY, 2013, 58 : 1221A - 1221A
  • [44] Impact of Sarcopenia on the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib
    Biselli, Maurizio
    Reggidori, Nicola
    Iavarone, Massimo
    Renzulli, Matteo
    Lani, Lorenzo
    Granito, Alessandro
    Piscaglia, Fabio
    Lorenzini, Stefania
    Alimenti, Eleonora
    Vara, Giulio
    Caraceni, Paolo
    Sangiovanni, Angelo
    Marignani, Massimo
    Gigante, Elia
    Brandi, Nicolo
    Gramenzi, Annagiulia
    Trevisani, Franco
    CANCERS, 2024, 16 (06)
  • [45] Early decrease in alfafetoprotein as a prognosis factor of response in patients with advanced hepatocellular carcinoma treated with sorafenib
    Maria Sanchez, Yolanda
    Ontanilla, Guillermo
    Teresa Ferrer, Maria
    Giraldez, Alvaro
    Manuel Sousa, Jose
    Manuel Pascasio, Juan
    HEPATOLOGY, 2016, 64 : 634A - 635A
  • [46] Effect of radiotherapy on survival in advanced hepatocellular carcinoma patients treated with sorafenib: a nationwide cancer-registry-based study
    Shou-Sheng Chu
    Yu-Hsuan Kuo
    Wen-Shan Liu
    Shih-Chang Wang
    Chung-Han Ho
    Yi-Chen Chen
    Ching-Chieh Yang
    Hung-Chang Wu
    Scientific Reports, 11
  • [47] Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study
    Hayashi, Tomoyuki
    Yamashita, Taro
    Terashima, Takeshi
    Suda, Tsuyoshi
    Okada, Hikari
    Asahina, Yoshiro
    Hayashi, Takehiro
    Hara, Yasumasa
    Nio, Kouki
    Sunagozaka, Hajime
    Takatori, Hajime
    Arai, Kuniaki
    Sakai, Yoshio
    Yamashita, Tatsuya
    Mizukoshi, Eishiro
    Honda, Masao
    Kaneko, Shuichi
    BMC CANCER, 2017, 17
  • [48] Sorafenib in advanced hepatocellular carcinoma
    Sauerbruch, T.
    Gonzalez-Carmona, A. M.
    Nitschmann, S.
    INTERNIST, 2009, 50 (11): : 1290 - 1292
  • [49] Hepatocellular carcinoma treated with sorafenib
    Han, G.
    Zhao, Y.
    Qi, X.
    Fan, D.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 34 (11-12) : 1347 - 1348
  • [50] Sorafenib in advanced hepatocellular carcinoma
    Llovet, Josep M.
    Ricci, Sergio
    Mazzaferro, Vincenzo
    Hilgard, Philip
    Gane, Edward
    Blanc, Jean-Frederic
    Cosme de Oliveira, Andre
    Santoro, Armando
    Raoul, Jean-Luc
    Forner, Alejandro
    Schwartz, Myron
    Porta, Camillo
    Zeuzem, Stefan
    Bolondi, Luigi
    Greten, Tim F.
    Galle, Peter R.
    Seitz, Jean-Francois
    Borbath, Ivan
    Haussinger, Dieter
    Giannaris, Tom
    Shan, Minghua
    Moscovici, Marius
    Voliotis, Dimitris
    Bruix, Jordi
    NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (04): : 378 - 390
12345